Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical company advancing tecarfarin, a novel oral anticoagulant targeting critical unmet needs in cardiovascular care. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely, verified information about tecarfarin's progress through Phase 3 trials and its potential applications for LVAD patients and rare cardiovascular conditions. Our news collection includes press releases on FDA designations, trial results, and collaborations with industry leaders in cardiac device therapy.
Key updates cover tecarfarin's unique metabolic profile designed to reduce drug interactions, its Orphan Drug status for specific indications, and progress toward addressing anticoagulation challenges in renal-impaired patients. All content is curated to support informed decision-making without promotional bias.
Bookmark this page for centralized access to Cadrenal Therapeutics' official announcements, including financial reports, clinical data publications, and partnership developments. Check regularly for updates on this innovative therapy's journey through late-stage clinical evaluation.
Cadrenal Therapeutics (NASDAQ: CVKD) reported its full year 2024 results and updates on tecarfarin development. The company secured a collaboration with Abbott for the TECH-LVAD Phase 3 trial and received additional FDA guidance through a Type D meeting.
Key financial highlights include:
- Net loss of $10.7M in 2024 vs $8.4M in 2023
- R&D expenses of $4.2M vs $4.1M in 2023
- G&A expenses increased to $6.8M from $3.5M
- Cash position of $10.0M as of December 31, 2024
- Raised $9.8M through ATM facility ($5.1M) and warrant exercises ($4.7M)
Notable achievements include FDA Orphan Drug Designation for tecarfarin in mechanical circulatory support devices, appointment of new executive leadership, and completion of manufacturing readiness for Phase 3 trial materials.
Cadrenal Therapeutics (CVKD) has announced a significant collaboration agreement with Abbott (ABT) to support their pivotal TECH-LVAD trial, evaluating tecarfarin in patients with Left Ventricular Assist Devices (LVADs).
The collaboration focuses on testing tecarfarin, a new oral Vitamin K antagonist (VKA), with Abbott's HeartMate 3™ LVAD, which is currently the only advanced mechanical circulatory support device available in the United States for patients with advanced heart failure.
Under the agreement, Abbott will provide support in:
- Trial design
- Site identification
- Trial awareness
- HeartMate 3™ expertise
The LVAD market, valued at $1.1 billion in 2023, is projected to reach $2.4 billion by 2032, according to Business Research Insights.
Cadrenal Therapeutics (CVKD) has appointed James J. Ferguson, MD, FACC, FAHA as its new Chief Medical Officer, replacing Douglas W. Losordo, MD. Dr. Ferguson, with over 25 years of cardiovascular leadership experience, will lead the late-stage clinical development of tecarfarin, a new Vitamin K antagonist, focusing on pivotal trials in LVAD patients and other rare cardiovascular conditions requiring life-long anticoagulation therapy.
Dr. Ferguson joins from Matinas BioPharma, where he served as Chief Medical Officer. His previous roles include Head of U.S. Cardiovascular Medical Affairs at Amgen and various senior positions at AstraZeneca. The appointment aims to advance tecarfarin's development as the first innovation in vitamin K-targeted anticoagulation in 70 years.
Cadrenal Therapeutics (Nasdaq: CVKD), a late-stage biopharmaceutical company, will deliver a presentation at the 2025 BIO CEO & Investor Conference at The New York Marriott Marquis on February 10-11, 2025. CEO Quang X. Pham will present on February 10 at 4:30 pm EST in the Royale Room, providing company updates and details about their lead product tecarfarin.
The presentation will focus on tecarfarin, a novel Vitamin K antagonist (VKA) being developed as a safer anticoagulant alternative to warfarin for patients with implanted cardiac devices. Mr. Pham will be available for one-on-one meetings through the BIO partnering portal during the conference.
Cadrenal Therapeutics (Nasdaq: CVKD) has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit, scheduled for January 13, 2025. The company's Chairman and CEO, Quang X. Pham, will engage in a virtual fireside chat at 10:30 a.m. Eastern time.
Cadrenal Therapeutics specializes in developing tecarfarin, a novel oral vitamin K antagonist (VKA) currently in advanced clinical development. This therapeutic is designed to provide a superior and safer anticoagulation alternative for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
The virtual event will be accessible through the conference website, with replay options available. Interested investors can request one-on-one meetings through Lytham Partners representatives.
Cadrenal Therapeutics (CVKD) provided its 2024 year-end update, highlighting progress in developing tecarfarin for left ventricular assist device (LVAD) patients and rare cardiovascular conditions. Key achievements include: FDA Orphan Drug Designation for tecarfarin in LVAD patients, successful fundraising of $9.8 million bringing cash balance to $11.3 million, and completion of manufacturing readiness for the upcoming Phase 3 trial.
The company held a Type B meeting with the FDA regarding the pivotal Phase 3 trial protocol, with updates expected in Q1 2025. Tecarfarin aims to provide a superior alternative to warfarin for chronic anticoagulation in LVAD patients. The company also joined the Anticoagulation Forum and was named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook.
Cadrenal Therapeutics (CVKD) announces its participation in three key events during the 43rd Annual J.P. Morgan Healthcare Conference Week in January 2025. The company will present updates on tecarfarin, their novel oral vitamin K antagonist designed for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
CEO Quang X. Pham will participate in the Longwood Healthcare Leaders discussions on January 11-12, attend the Nasdaq Opening Bell Ceremony on January 13, and along with COO Jeff Cole, will conduct one-on-one investor meetings during the conference. The company plans to outline its Phase 3 clinical development plan, regulatory approval strategy, and three-year vision.
Cadrenal Therapeutics (Nasdaq: CVKD) has been named '2024 Anticoagulation Therapy Company of the Year' by Pharma Tech Outlook for its development of tecarfarin, a new vitamin K antagonist anticoagulant. The company is developing tecarfarin as a potentially safer alternative to warfarin for patients with implanted left ventricular assist devices (LVADs) and rare cardiovascular conditions. Unlike warfarin, tecarfarin uses a unique metabolic pathway less affected by drug-drug interactions and kidney impairment. The drug has received orphan drug and fast-track designations, positioning it to address unmet needs in chronic anticoagulation treatment.
Cadrenal Therapeutics (CVKD) highlighted a presentation at the EACTS Medical Congress featuring tecarfarin data and their proposed clinical trial protocol. The presentation, titled Tecarfarin and Hemocompatibility with LVAD Therapy (TECH-LVAD), focused on evaluating tecarfarin versus warfarin in patients with Abbott HeartMate3 left ventricular assist device. Dr. Mandeep R. Mehra presented data showing the relationship between bleeding rates and time in therapeutic range for HM3 patients, and evidence of tecarfarin's potential to improve TTR. The presentation also highlighted that end-stage kidney disease doesn't alter tecarfarin exposure, unlike warfarin, which is significant as many LVAD patients have kidney impairment.
Cadrenal Therapeutics (NASDAQ: CVKD) provided a Q3 2024 corporate update highlighting progress in developing tecarfarin, a new vitamin K antagonist for anticoagulation. Key developments include FDA discussions regarding Phase 3 trial protocol for LVAD patients, advancement of Abbott collaboration talks, and joining the Anticoagulation Forum's Corporate Council. The company successfully raised $9.8 million through ATM and warrant exercises, increasing cash balance to $11.3 million. Q3 operating expenses were $2.5 million, with $2.2 million used in operating activities. Tecarfarin is positioned as the only anticoagulant in development for patients with implanted cardiac devices and rare cardiovascular conditions.
FAQ
What is the current stock price of Cadrenal Therape (CVKD)?
What is the market cap of Cadrenal Therape (CVKD)?
